Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
Vitelliform Macular Dystrophy
Welcome,
Profile
Billing
Logout
2 Companies
1 Product
1 Product
3 Mechanisms of Action
0 Trials
3 News
|
|||||||||
Lucentis
(ranibizumab) /
Roche, Novartis
Enrollment change:
FVF4140S: Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
(clinicaltrials.gov) - Oct 23, 2012
P1/2
, N=18, Completed,
Sponsor: Manhattan Eye, Ear & Throat Hospital
N=40 --> 18
|
|||||||||
Lucentis
(ranibizumab) /
Roche, Novartis
Trial completion:
FVF4140S: Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
(clinicaltrials.gov) - Oct 23, 2012
P1/2
, N=18, Completed,
Sponsor: Manhattan Eye, Ear & Throat Hospital
N=40 --> 18 Recruiting --> Completed